DIRS.INFO The most relevant business & tech news

☆ Amgen wants in on the booming weight loss drug market — and it's taking a different approach
▼ + stars: | 2024-03-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Mario Tama | Getty ImagesAmgen is taking a new approach as it tries to stand out in a crowded field of drugmakers racing to develop the next blockbuster weight loss drug. It's too early to say how competitive Amgen will be in the budding weight loss drug space, which Novo Nordisk and Eli Lilly have so far dominated. Goldman Sachs also projects that between 10 million and 70 million Americans will be taking weight loss drugs by 2028. The sustained weight loss in Amgen's study appears to contrast with results seen in clinical trials on Zepbound and Wegovy. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023.

Persons: Mario Tama, Eli Lilly, Goldman Sachs, Zepbound, Eli Lilly's, Amgen's MartiTide, Caroline Apovian, Apovian, Joe Buglewicz, MariTide, Holly Lofton, Eli Lilly’s, Brendan McDermid, Reuters Amgen's, William Blair, Matt Phipps, Phipps Organizations: Getty, Novo Nordisk, Pfizer, Viking Therapeutics, Therapeutics, Zealand Pharma, Boehringer, Center, Weight Management, Wellness, Brigham, Women's, Washington Post, NYU Langone Health, Reuters, William Blair & Company, CNBC Locations: Thousand Oaks , California, Oaks , California, Novo, New York City, U.S

By comparison, a group of people who also dieted and exercised, but then received dummy shots, lost weight initially but then regained some, researchers reported Sunday in the journal Nature Medicine. Participants in both groups lost about 7% of their body weight, or almost 17 pounds (8 kilograms), during the diet-and-exercise phase. Those who received the drug went on to lose an additional 18.4% of initial body weight, or about 44 pounds (20 kilograms) more, on average. Nearly 29% of those taking the drug lost at least a quarter of their body weight, compared with just over 1% of those taking placebo. Side effects including nausea, diarrhea and constipation were reported more frequently in people taking the drug than those taking the placebo.

Persons: Mounjaro, ”, Thomas Wadden, Eli Lilly, it's, Caroline Apovian, wasn't, tirzepatide, “, Lilly Organizations: Nature, University, Pennsylvania, Brigham, Women's, Novo Nordisk, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, ”

☆ Forget TikTok claims: ‘Nature’s Ozempic’ is no such thing, experts say
▼ + stars: | 2023-07-04 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +6 min

CNN —If TikTok and Reddit influencers are to be believed, the plant-based compound called berberine can be a replacement for such popular diabetes and weight loss drugs as Ozempic and Wegovy. Is berberine’s weight loss effect meaningful? Berberine may enhance the body’s natural production of GLP-1, or glucagon-like peptide 1, a gastrointestinal hormone that’s used in Ozempic and other new weight loss drugs. However, in terms of its weight loss benefits, they are modest at best,” he said. “Metformin lowers blood sugar, and berberine lowers blood sugar,” Levitt said.

Persons: Berberine, “, ”, Caroline Apovian, Justin Ryder, Ryder, Joshua Levitt, Ashurbanipal, ” Levitt, Gaston Ernesto Gonzalez Avila, Levitt Organizations: CNN, US Food and Drug Administration, Harvard Medical School, Center, Weight Management, Wellness, Brigham, Women’s Hospital, Northwestern University’s Feinberg School of Medicine, BMI, National Library of Medicine, FDA, American Chemical Society Locations: Boston, Chicago, Ayurveda, Hamden , Connecticut

☆ Obesity changes the brain, with ‘no sign of reversibility,’ researchers find
▼ + stars: | 2023-06-12 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

“This study captures why obesity is a disease — there are actual changes to the brain,” said Apovian, who was not involved in the study. They wanted to know if that would be different in people with obesity compared to those of normal weight. At the same time, levels of dopamine rose in those at normal weight, signaling that the reward centers of the brain were also activated. Losing weight did not reset the brain in people with obesity, Serlie said. Until science answers these questions, the study emphasizes, once again, that weight stigma has no place in the fight against obesity, Serlie said.

Persons: ’ ”, Caroline Apovian, ”, Apovian, Sadaf, they’ve, “, Mireille Serlie, ” Faroof, ” Serlie, Farooqi, Serlie, it’s, ” Farooqi, ‘ Organizations: CNN, Harvard Medical School, Center, Weight Management, Wellness, Brigham, Women’s Hospital, BMI, University of Cambridge, Yale School of Medicine Locations: Boston, New Haven , Connecticut

☆ As weight-loss drugs hit the U.S. market, doctors debate how to use them
▼ + stars: | 2023-03-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +6 min

[1/2] The American Medical Association logo is seen at their office in Washington, D.C., U.S., August 30, 2020. REUTERS/Andrew Kelly/March 30 (Reuters) - As powerful new obesity drugs enter the U.S. market, medical associations are keen to advise their members on how to best use them for patients. "These new compounds are game changers, there's no doubt about it," said Anthony Comuzzie, chief executive of The Obesity Society. The group last provided obesity treatment guidelines in 2013 alongside the American Heart Association and American College of Cardiology. OBESITY AS A DISEASEThe American Medical Association, the nation’s largest medical group, recognized obesity as a disease in 2013.

Search resuls for: "Apovian"

5 mentions found